CJC-1295 Benefits, Dosing & DAC vs No-DAC

CJC-1295 is one of the most heavily marketed growth-hormone peptides, usually sold by clinics and "research chemical" sites as a longer-lasting way to raise your own growth hormone (GH). The pitch is appealing: fewer injections, a sustained signal, and a long list of promised benefits — more muscle, less fat, better sleep, faster recovery, anti-aging. The reality is narrower and more honest than the marketing. CJC-1295 reliably does one thing in humans that has actually been measured: it raises GH and the downstream hormone IGF-1, and the "with DAC" version keeps them elevated for days. Almost everything beyond that — the body-composition and longevity claims — rests on mechanism and extrapolation, not on outcome trials. This guide separates what is documented from what is sold.

What CJC-1295 actually is

CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH) — specifically a modified version of the GHRH(1-29) fragment, the same short active fragment that sermorelin is based on. Like all GHRH analogs, it works upstream: instead of injecting GH directly, it binds the GHRH receptor on your pituitary and prompts your own pulsatile GH release, which then raises IGF-1. The design twist is durability. Native GHRH and sermorelin are chewed up within minutes by the enzyme DPP-IV; CJC-1295 carries amino-acid substitutions that resist that breakdown, and — in its "with DAC" form — an added Drug Affinity Complex that latches onto albumin in your blood so the peptide circulates for days rather than minutes.

DAC vs no-DAC: the difference that actually matters

If you take one thing from this article, make it the DAC distinction — because "CJC-1295" is sold as two pharmacologically different things under one name.

CJC-1295 with DAC is the long-acting version. In the only well-documented human study — a pharmacokinetic and safety trial in healthy adults — single doses raised GH for up to about six days and IGF-1 for roughly nine to eleven days, with mean IGF-1 staying above baseline for over a week at the higher doses¹. That is the entire engineering goal: a flat, sustained, once-or-twice-weekly signal instead of frequent injections.

CJC-1295 without DAC — often labeled "modified GRF 1-29" — lacks the albumin-binding group. It is short-acting and behaves much more like sermorelin: a brief, pulsatile GH bump that clears quickly. People choose it specifically because a short pulse is closer to how your body naturally secretes GH. The catch: a product labeled only "CJC-1295" may not tell you which one you are getting, and the two are not interchangeable. (For the head-to-head with the shorter peptide it is modeled on, see sermorelin vs CJC-1295, and for how half-life shapes dosing generally, sermorelin's half-life.)

The benefits people claim — and what the evidence really shows

Here is the honest core. The benefit that is genuinely documented in humans is biochemical: CJC-1295 raises GH and IGF-1, and with DAC it sustains that elevation for days¹. That study was a pharmacokinetic and tolerability report in healthy volunteers — not a trial of muscle, fat, strength, sleep, recovery, or longevity. No modern randomized controlled trial has shown that CJC-1295 improves body composition or any real-world outcome in people.

So why do the muscle-and-anti-aging claims persist? They are inferred from two true premises that don't combine into proof. First, GH secretion genuinely declines with age and with greater visceral fat⁴ — real physiology. Second, CJC-1295 raises GH and IGF-1 short-term¹. Stack those together and the marketing concludes "therefore it restores youthful body composition." But "raises a hormone that falls with age" is not the same as "reverses the effects of aging," and the trial that would test the claim does not exist for CJC-1295. The closest controlled signal for any GHRH analog affecting an aging-related outcome comes from a separate trial of a different analog that found cognitive effects alongside raised IGF-1 in older adults⁵ — investigational research on another molecule, not proof for CJC-1295. We hold that line throughout our pillar guide to sermorelin's sleep and recovery evidence.

It is worth naming the comparison class honestly. Sermorelin, the short GHRH(1-29) peptide, has its own best-known human study — single nightly injections raised GH and IGF-1 in healthy elderly men² — and a documented role as a diagnostic test of pituitary GH reserve³. That is a longer, if still modest, paper trail than CJC-1295 has. In other words, the more heavily marketed, longer-acting peptide actually has less human evidence behind it, not more.

Dosing: why "as prescribed" is the only defensible answer

Because CJC-1295 has no FDA-approved finished product and no established human dosing label, every protocol you will see online is clinic convention or forum lore, not validated dosing. A few principles are grounded in the pharmacology rather than the marketing:

• •DAC changes the schedule entirely. The with-DAC version's days-long action¹ is why it is dosed once or twice weekly, while no-DAC "modified GRF 1-29" is dosed more like sermorelin — small, frequent, often bedtime injections to mimic a natural pulse.
• •CJC-1295 is frequently "stacked" with a GHRP. Clinics commonly pair it with ipamorelin (a selective ghrelin-receptor secretagogue⁶) because GHRH analogs and GH-releasing peptides act on different receptors and can amplify GH release together⁷ — a real, measured synergy, though the long-term human outcome data for the combination is sparse. We cover that pairing in the sermorelin + ipamorelin stack.
• •Timing and food matter pharmacologically. A carbohydrate-driven insulin spike blunts the GH response to GHRH⁸, which is the rationale behind the common "inject on an empty stomach" guidance — though this is mechanistic reasoning applied to CJC-1295, not a dosing rule proven in a CJC-1295 trial.

None of this licenses self-dosing. The sustained IGF-1 elevation the DAC version produces is exactly the kind of signal a prescriber would want to monitor (see safety, below).

Safety, monitoring, and the supply problem

Two cautions deserve equal weight. The first is physiological. Because CJC-1295 raises GH and IGF-1 — and with DAC sustains a flat, non-pulsatile elevation rather than the brief natural pulses¹ — the relevant monitoring is IGF-1 levels and glucose handling, since elevating the GH/IGF-1 axis can affect insulin sensitivity. The long-term consequences of a days-long, non-physiologic IGF-1 signal in otherwise healthy people simply have not been studied in proper trials.

The second is the supply chain. CJC-1295 was never an FDA-approved marketed drug; it appears in the literature largely as an investigational compound and, increasingly, as a doping-control analyte. Methods exist specifically to confirm CJC-1295 abuse⁹, it features in broader work on detecting synthetic GHRH analogs¹⁰, and analyses of online doping markets document how such peptides are traded through unregulated forums¹¹. Translated out of journal language: a large share of the CJC-1295 supply is grey-market, sold "for research use only," with no guarantee of identity, purity, dose, or sterility. A peptide obtained that way carries risks that have nothing to do with the molecule itself.

The bottom line

CJC-1295's one documented human benefit is that it raises GH and IGF-1, and the DAC version sustains that rise for days from a single dose — a real pharmacologic effect, established in a short safety study, not a proven path to muscle, fat loss, better sleep, or longevity. The DAC-versus-no-DAC split is the most important practical distinction, because the two versions are dosed and behave very differently and are sold under the same name. Treat any use as an off-label, monitored prescription decision rather than a supplement, be wary of grey-market sourcing, and don't mistake a longer half-life — or a longer marketing claim — for a stronger result. If you're weighing GHRH analogs for a sleep-and-recovery goal, compare the options in sermorelin vs CJC-1295 and see how the providers offering these peptides stack up in our guide to the best sermorelin providers.